Wellumio

Wellumio operates in medical devices and manufacturing, with a focus on portable neuroimaging and urgent stroke assessment. Its Axana system is designed to bring MRI closer to the patient, while Pulsed Gradient Free Mapping and the Stroke-GPS AI engine distinguish its stated approach from conventional imaging workflows. The company also describes imaging contrasts including T1, T2, T2 Flair, DWI, and perfusion, and supports serial imaging for monitoring changing conditions. These characteristics place it in the broader brain-imaging and point-of-care diagnostics landscape, where established imaging manufacturers and emerging portable-imaging developers are relevant comparison groups. However, the available company profile does not identify named competitors, and the similarity entries contain only Wellumio itself; naming specific rival companies would therefore be speculative. Its disclosed scale is small, at 1–10 employees, and its funding history includes a $9.75 million round reported in July 2026. The market-position question is consequently less about demonstrated scale than whether its portable hardware, imaging method, and AI-assisted interpretation can translate into validated clinical utility, regulatory clearance, and adoption in time-sensitive stroke pathways.

Founded in 2019, Wellumio has developed from a New Zealand medical-technology venture into a company pursuing clinical testing and overseas expansion. Its 2023 funding history includes a structured Seed round of approximately $1.67 million and two recorded grants, while a separate financial signal gives a $4.25 million Seed figure for 2023. Those figures may represent a conflicting or differently defined account of the same financing, so they should not be added without clarification. In 2024, the company received a further recorded grant. The first major execution inflection visible in the timeline came in January 2025, when Wellumio announced U.S. expansion and a Menlo Park subsidiary; in February, it reported that the first patient had entered an Australian Axana clinical trial. The next financing milestone was a $9.75 million round reported on Jul 24, 2026 as Pre-Series A, although a structured entry records the same amount as a Seed round dated Feb 10, 2026. Its employee band remains 1–10, and hiring signals cite engineering, business operations, and finance, including Harry Marfatia as Head of Finance. Future trajectory depends on clinical evidence, regulatory progress, and execution across these markets.